Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer (2024)

Peer-Reviewed Study · Hayashi A, Kamio K, Miyanaga A, Yoshida K, Noro R, Matsuda K, Tozuka T, Omori M, Hirao M, Fukuizumi A, Hisakane K, Takeuchi S, Matsumoto M, Kasahara K, Amano T, Honda K, Seike M · December 2024

Hayashi A et al., 2024-12: Lung (NSCLC) cell study: ivermectin plus paclitaxel inhibited A549 growth and prevented paclitaxel resistance by suppressing P-glycoprotein via EGFR/ERK/Akt/NF-kB.

Notably, the simultaneous ivermectin treatment during the gradual exposure completely abolished P-gp expression, leading to an increased intracellular PTX concentration and sustained PTX sensitivity.

Hayashi A et al., 2024-12: Lung (NSCLC) cell study: ivermectin plus paclitaxel inhibited A549 growth and prevented paclitaxel resistance by suppressing P-glycoprotein via EGFR/ERK/Akt/NF-kB. C7 lung cancer. Study type: cell lines only (A549 and a paclitaxel-resistant derivative); no animals, no patients. Country: Japan (Nippon Medical School, Tokyo; RIKEN). Concentration: not stated in the abstract captured. Funder/conflicts: not captured in the PubMed record. Comparator: paclitaxel alone, and drug-sensitive parental cells. Records an effect of the COMBINATION and of co-administration during resistance induction – it does not report single-agent ivermectin tumour regression or any clinical outcome. Also filed as IVC-30 (claims C5, C7). Study type: lab.